Eisai, Arena ask FDA to bless extended-release Belviq; J&J files for Stelara nod in Crohn's;

@FiercePharma: Japan reaping the benefits from faster approval process. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce: last week: FDA warning letter says Dr Reddy's hid existence of QC testing lab where retesting was done. Report | Follow @EricPFierce

@CarlyHFierce: last week: Trump, Clinton lash out at Pfizer over Allergan deal agreement. Article | Follow @CarlyHFierce

> Eisai and Arena Pharmaceuticals ($ARNA) said the FDA accepted their application for approval of an extended-release version of their anti-obesity med Belviq. Release

> Johnson & Johnson ($JNJ) asked the FDA to approve expanded use of its anti-inflammatory drug Stelara, for patients with Crohn's Disease; the drug is already used to treat psoriasis and psoriatic arthritis. Release

> One analyst's survey found that 90% of industry respondents think Pfizer ($PFE) will hive off its established products unit after its proposed $160 billion megamerger with Allergan ($ACT). Report

Medical Device News

@FierceMedDev: From FierceDrugDelivery: Adapt Pharma earns FDA approval of first intranasal spray for emergency opioid overdose. Article | Follow @FierceMedDev

@VarunSaxena2: AstraZeneca begins dosing in trial of its Bind-partnered cancer candidate. More from FierceDrugDelivery | Follow @VarunSaxena2

@EmilyWFierce: A behind-the-scenes look at Cards Against Biotechnology, Cubist's snarky 'last hurrah': FiercePharmaMarketing item | Follow @EmilyWFierce

> Nevro scores a victory in spinal cord stimulation patent battle with Boston Scientific. Article

> Q&A: Philips on what's next after the first year of HealthTech. Report

Biotech News

@FierceBiotech: Real R&D innovation demands that lines between academia and industry are blurred. Article | Follow @FierceBiotech

@JohnCFierce: Disgraced scientist's China venture resurrects fears of a human cloning comeback. Story | Follow @JohnCFierce

@DamianFierce: Actually, inversions are ... good? More from the NYT | Follow @DamianFierce

> Foundering Xoma flips its diabetes program to Novo Nordisk in a $295M deal. Report

> For real R&D innovation, blur the lines between pharma and academia: Panel. Editor's corner

> FDA to Repros: Wipe your PhIII drawing board clean and start over. More

> Puma preps its once-vaunted cancer drug for European submission. Article

Pharma Manufacturing News

> Xellia buys idled Bedford plant from Hikma, will hire 170. Report

> FDA warning letter blasts Dr. Reddy's for undisclosed testing. News

> Samsung BioLogics to build its third and largest plant in South Korea. Story

> Meda sells off Spain operation that makes Legalon API. Article

> GE investing $40M in Ireland plant and will add 140 jobs. Item

Pharma Asia News

> Pharmaceuticals in South Korea could drive economy's growth. Item

> Survey: Rates of HIV in Asia could reflect 'hidden epidemic.' More

> Israel's Teva and Takeda tie up for Japan generics business. Report

> Delhi court rules for Dr. Reddy's in Xarelto case. Story

> Russia hopes to lure drugmakers with increase in buying power. Article

Drug Delivery News

> Nature: Electronic on-demand delivery device is also bioresorbable. More

> Indian Institute of Science develops hep C delivery vehicle using siRNA. Story

> UCSD develops tech to isolate drug-delivery nanoparticles from the blood. Item

> Presage licenses cancer drug from India's Piramal to accelerate development using its microinjector. Report

> Impax earns permission to sell its FDA-approved modified-release Parkinson's med in Europe. Article

And Finally... Light therapy, often used to treat seasonal depression, may work for the non-seasonal kind, a study found. Report

Suggested Articles

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.

Gilead CEO promised to make remdesivir affordable, shortly after the company backed off its request for orphan status amid a public backlash.